Jeong Yun Yang
Overview
Explore the profile of Jeong Yun Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Artin M, Soddano J, Rustgi S, Aziz Z, Lim F, Yang J, et al.
Gastro Hep Adv
. 2025 Feb;
4(4):100602.
PMID: 39996244
Background And Aims: Helicobacter pylori (H. pylori) is a major cause of peptic ulcer disease (PUD) and upper gastrointestinal bleeding. Testing for and eradication of H. pylori reduces the risk...
2.
Wang C, McKinley M, Vu A, Yang J, Gupta S, Gomez S, et al.
Gastro Hep Adv
. 2024 Aug;
3(4):482-490.
PMID: 39131721
Background And Aims: Gastrointestinal cancer incidence varies by race and ethnicity. In the United States (US), there are screening guidelines for esophageal cancer (EC) and colorectal cancer (CRC), but not...
3.
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, et al.
Clin Gastroenterol Hepatol
. 2023 Jan;
21(6):1598-1606.e5.
PMID: 36642291
Background & Aims: Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis...
4.
Baseline Cannabinoid Use Is Associated with Increased Sedation Requirements for Outpatient Endoscopy
Nasser Y, Biala S, Chau M, Partridge A, Yang J, Lethebe B, et al.
Cannabis Cannabinoid Res
. 2022 Oct;
9(1):310-319.
PMID: 36269560
Given the underlying properties of cannabinoids, we aimed to assess associations between cannabinoid use and sedation requirements for esophagogastroduodenoscopy (EGD) and colonoscopy. A prospective cohort study was conducted at three...
5.
Yang J, Baeg K, Martin J, Wisnivesky J, Kim M
Pancreas
. 2022 Jan;
50(10):e81-e82.
PMID: 35041348
No abstract available.
6.
Aroniadis O, Wang X, Gong T, Forbes N, Yang J, Canakis A, et al.
Dig Dis Sci
. 2021 Nov;
67(8):3860-3871.
PMID: 34751837
Background And Aims: The most common symptoms of Covid-19 are respiratory; however, gastrointestinal symptoms are present in up to 50% of patients. We aimed to determine characteristics associated with the...
7.
Pan D, Ip A, Zhan S, Wasserman I, Snyder D, Agathis A, et al.
Heart Lung
. 2021 Jun;
50(5):618-621.
PMID: 34090177
Objective: To evaluate the association between pre-hospitalization antiplatelet medication use and COVID-19 disease severity. Design: Retrospective cohort study. Setting: Inpatient units at The Mount Sinai Hospital. Patients: Adults age ≥18...
8.
Rustgi S, Oh A, Yang J, Kang D, Wolin E, Kong C, et al.
BMC Cancer
. 2021 May;
21(1):597.
PMID: 34030646
Background & Aims: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous neoplasms. Although some have a relatively benign and indolent natural history, others can be aggressive and ultimately fatal. Somatostatin analogues (SSAs)...
9.
Ni K, Yang J, Baeg K, Leiter A, Mhango G, Gallagher E, et al.
Cancer Rep (Hoboken)
. 2021 Apr;
4(5):e1387.
PMID: 33835729
Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasingly common malignancies and tend to have favorable long-term prognoses. Somatostatin analogues (SSA) are a first-line treatment for many NETs. Short-term experiments suggest an...
10.
Rustgi S, Yang J, Luther S, David Y, Dixon R, Simoes P, et al.
Clin Res Hepatol Gastroenterol
. 2021 Feb;
45(3):101602.
PMID: 33607549
No abstract available.